221 related articles for article (PubMed ID: 28814166)
41. Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.
Sato DK; Callegaro D; Lana-Peixoto MA; Nakashima I; Fujihara K
Arq Neuropsiquiatr; 2014 Jun; 72(6):445-50. PubMed ID: 24964112
[TBL] [Abstract][Full Text] [Related]
42. Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Niino M; Uesugi H; Takahashi T; Fukazawa T; Minami N; Tashiro J; Fujiki N; Doi S; Kikuchi S
Intern Med; 2012; 51(7):809-12. PubMed ID: 22466845
[TBL] [Abstract][Full Text] [Related]
43. Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.
Hacohen Y; Messina S; Gan HW; Wright S; Chandratre S; Leite MI; Fallon P; Vincent A; Ciccarelli O; Wassmer E; Lim M; Palace J; Hemingway C
Mult Scler; 2018 Apr; 24(5):679-684. PubMed ID: 28803524
[TBL] [Abstract][Full Text] [Related]
44. Neuromyelitis optica spectrum disorder with massive basal ganglia involvement: a case report.
Ohara S; Miyahira TA; Oguchi K; Takei YI; Yanagimura F; Kawachi I; Oyanagi K; Kakita A
BMC Neurol; 2019 Dec; 19(1):351. PubMed ID: 31888527
[TBL] [Abstract][Full Text] [Related]
45. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder.
Creed MA; Ballesteros E; Jr LJG; Imitola J
Mult Scler Relat Disord; 2020 Sep; 44():102199. PubMed ID: 32554285
[TBL] [Abstract][Full Text] [Related]
46. Neuromyelitis Optica Spectrum Disorder Complicated by Posterior Reversible Encephalopathy Syndrome as an Initial Manifestation.
Shima T; Tsujino S; Yamashita K; Hirayama T; Fukushima K; Kanamoto T; Ohta R; Nagaoka A; Yoshimura S; Miyazaki T; Tateishi Y; Shiraishi H; Tsujino A
Intern Med; 2020 Aug; 59(15):1887-1890. PubMed ID: 32321890
[TBL] [Abstract][Full Text] [Related]
47. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
48. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders.
Wang X; Yi H; Liu J; Li M; Mao ZF; Xu L; Peng FH
J Neurol Sci; 2016 Jul; 366():3-7. PubMed ID: 27288767
[TBL] [Abstract][Full Text] [Related]
49. Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review.
Wang KY; Chetta J; Bains P; Balzer A; Lincoln J; Uribe T; Lincoln CM
Br J Radiol; 2018 Jun; 91(1086):20170690. PubMed ID: 29388807
[TBL] [Abstract][Full Text] [Related]
50. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
[TBL] [Abstract][Full Text] [Related]
51. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
52. Normal-appearing white matter demyelination in neuromyelitis optica spectrum disorder.
Jeong IH; Choi JY; Kim SH; Hyun JW; Joung A; Lee J; Kim HJ
Eur J Neurol; 2017 Apr; 24(4):652-658. PubMed ID: 28233435
[TBL] [Abstract][Full Text] [Related]
53. Demyelinating syndrome in systemic sclerosis and neuromyelitis optica.
Deeb K; Eby J; Labault-Santiago J
BMC Neurol; 2019 Oct; 19(1):234. PubMed ID: 31607267
[TBL] [Abstract][Full Text] [Related]
54. A case of anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder with MRI-proven lesions in lumbar nerve roots.
Toru S; Soejima I; Katayama Y; Saito K; Yokote H
Mult Scler Relat Disord; 2020 Nov; 46():102557. PubMed ID: 33296967
[TBL] [Abstract][Full Text] [Related]
55. Intractable nausea and vomiting as an uncommon presentation in an anti-aquaporin 4-positive patient.
Wang L; Su HJ; Qi JL; E RF; Zhao K
J Int Med Res; 2018 Aug; 46(8):3411-3416. PubMed ID: 29806512
[TBL] [Abstract][Full Text] [Related]
56. Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder.
Sun H; Cui S; Gao F; You Q; Li Y; Wang J; Zhang X
J Neurol Sci; 2018 Jan; 384():91-95. PubMed ID: 29249386
[TBL] [Abstract][Full Text] [Related]
57. Neuromyelitis Optica and Herpes Simplex Virus 2: A Viral Trigger for Aquaporin-4 Autoimmunity?
Marin Collazo IV; Howe CL; Lucchinetti CF; Tobin WO
Neurologist; 2018 May; 23(3):92-93. PubMed ID: 29722742
[TBL] [Abstract][Full Text] [Related]
58. [The role of aquaporin 4 antibody in the injury of retinal microstructure in neuromyelitis optica spectrum disorders].
Wang ZW; Wang QQ; Diao DW; Guo QF; Qi XK
Zhonghua Nei Ke Za Zhi; 2018 Jun; 57(6):435-439. PubMed ID: 29925129
[No Abstract] [Full Text] [Related]
59. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Stellmann JP; Krumbholz M; Friede T; Gahlen A; Borisow N; Fischer K; Hellwig K; Pache F; Ruprecht K; Havla J; Kümpfel T; Aktas O; Hartung HP; Ringelstein M; Geis C; Kleinschnitz C; Berthele A; Hemmer B; Angstwurm K; Young KL; Schuster S; Stangel M; Lauda F; Tumani H; Mayer C; Zeltner L; Ziemann U; Linker RA; Schwab M; Marziniak M; Then Bergh F; Hofstadt-van Oy U; Neuhaus O; Zettl U; Faiss J; Wildemann B; Paul F; Jarius S; Trebst C; Kleiter I;
J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):639-647. PubMed ID: 28572277
[TBL] [Abstract][Full Text] [Related]
60. Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level.
Nishimura H; Enokida H; Sakamoto T; Takahashi T; Hayami H; Nakagawa M
J Artif Organs; 2018 Sep; 21(3):378-382. PubMed ID: 29675599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
